The immune system of intensively reared turkeys is constantly exposed to a number of factors impairing its functioning, although it is with viral infections that immunosuppression in these birds is most often associated. A distinctive feature of immunosuppressive pathogens is their special affinity for the organs and cells of the immune system. In Poland, one of the most commonly reported pathogens causing immunosuppression in turkeys is haemorrhagic enteritis virus (HEV), which is a member of the
Infection with the virus causing this disease, which is usually asymptomatic, results in impaired immune function (38, 40, 45, 47). The immunosuppressive effect of HEV on the turkey leads to an aggravation of pre-existing diseases and infections with opportunistic microorganisms, most often
Infection with the virus causing this disease, which is usually asymptomatic, results in impaired immune function (38, 40, 45, 47). The immunosuppressive effect of HEV on the turkey leads to an aggravation of pre-existing diseases and infections with opportunistic microorganisms, most often
The aim of this study was to investigate the influence of two kinds of immunomodulator on the immune response of experimentally HEV-infected turkeys. The immunomodulators were synthetic methisoprinol and natural β-1,3/1,6 glucans with MOS. The preparations were administered before, after, or both before and after HEV infection of turkeys and their effect was observed on IFN-γ synthesis by CD4+ and CD8α+ T cells isolated from turkey spleens in response to mitogenic stimulation
In the first experiment, turkeys in the I-M/HEV+ and I-M/HEV− groups received methisoprinol from 39 to 41 days of life (dol) and turkeys in the I-B/HEV+ and I-B/HEV− groups received Alphamune G from 28 to 41 dol. This was before they were experimentally infected with the HE virus, which was carried out at 42 dol.
In the second experiment, turkeys in the II-M/HEV+ and II-M/HEV− groups received methisoprinol and turkeys in the II-B/HEV+ and II-B/HEV− groups received Alphamune G for 5 days from 43 to 47 dol and therefore after infection with HEV.
In the third experiment, turkeys in the III-M/HEV+ and III-M/HEV− groups received methisoprinol from 39 to 47 dol and turkeys in the III-B/HEV+ and III-B/HEV− groups received Alphamune G from 28 to 47 dol, which was before and after the HEV infection at 42 dol.
Turkeys in the C/HEV+ and C/HEV− groups were controls and did not receive the immunomodulators.
EID50)/bird using an oesophageal cannula. Birds that were not infected with HEV received 1 mL of phosphate-buffered saline (PBS) by the same route.
Experimental design
Group | Day of life/day post infection |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 2–27 | 28–38 | 39–41 | 42/0 | 43/1 | 44/2 | 45/3 (S) | 46/4 | 47/5 (S) | 48/6 | 49/7 (S) | |
I-M/HEV+ | EI | |||||||||||
I-M/ HEV− | Meth | PBS | ||||||||||
I-B/HEV+ | β-Glu + MOS | EI | ||||||||||
I-B/HEV− | PBS | |||||||||||
II-M/HEV+ | Random | EI | ||||||||||
II-M/ HEV− | division of | PBS | Meth | |||||||||
II-B/HEV+ | chicks into | Rearing | EI | |||||||||
II-B/ HEV− | 14 groups of | under | PBS | β-Glu + MOS | ||||||||
20 birds | standard | EI | ||||||||||
HEV+ III-M/ | each and | techniques | Meth | |||||||||
introduction | and | Meth | PBS | Meth | ||||||||
III-M/HEV− | into | procedures | Meth | |||||||||
experimental | EI | |||||||||||
HEV+ III-B/ | boxes | β-Glu+MOS | ||||||||||
− | β-Glu + MOS | PBS | β-Glu + MOS | |||||||||
III-B/HEV | β-Glu+MOS | |||||||||||
C/HEV+ | EI | |||||||||||
C/ HEV− | PBS |
I-M – turkeys immunomodulated with methisoprinol prior to infection; I-B – turkeys immunomodulated with β-glucans and mannan oligosaccharides (MOS) prior to infection; II-M – turkeys immunomodulated with methisoprinol after infection; II-B – turkeys immunomodulated with β-glucans and MOS after infection; III-M – turkeys immunomodulated with methisoprinol prior to, at the time of, and after infection; III-B – turkeys immunomodulated with β-glucans and MOS prior to, at the time of, and after infection; C – control turkeys not receiving immunomodulators; HEV+ – turkeys infected with haemorrhagic enteritis adenovirus at 42 days of life; HEV− – uninfected turkeys; EI – experimental infection with HEV at a dose of 104.3 50% egg infectious dose (EID50); PBS – uninfected turkeys receiving 1 mL of sterile phosphate buffered saline; Meth – methisoprinol administered in drinking water at 200 mg/kg b.w.; β-Glu+MOS – β-glucans and MOS administered at 500 g of Alphamune G per tonne of feed; S – sampling of the spleen from four turkeys of each group
All homogenised samples were then frozen at −22°C and thawed to +4°C three times to lyse the virus from the cells. Genomic DNA was isolated with the use of a Genomic Mini kit (A&A Biotechnology, Gdańsk, Poland), in accordance with the procedure provided by the manufacturer. Details of the method for detecting the HEV hexon gene fragment in samples were described previously (30).
Mean percentage of IFN-γ+ cells (±SD) in splenic CD4+ T lymphocytes collected from the examined turkeys receiving immunomodulators before the day of infection with HEV
Group | Mean percentage of CD4+IFN-γ+ T cells (±SD) |
||
---|---|---|---|
3 dpi | 5 dpi | 7 dpi | |
I-M/HEV+ | 3.64c (±0.45) | 10.58a (±2.44) | 11.29a (±1.15) |
I-M/HEV− | 3.04c (±1.36) | 3.69c (±0.38) | 4.75cd (±0.90) |
I-B/HEV+ | 2.31c (±0.32) | 9.12ab (±0.87) | 6.38bc (±1.85) |
I-B/HEV− | 7.22a (±2.50) | 5.77cd (±0.92) | 8.74b (±0.94) |
C/HEV+ | 2.26c (±0.41) | 7.20bd (±1.32) | 3.54cd (±0.45) |
C/HEV− | 5.47b (±1.45) | 7.03bd (±0.98) | 4.52cd (±0.17) |
IFN-γ+ – interferon gamma–positive; SD – standard deviation; dpi – days post infection; I-M – turkeys immunomodulated with methisoprinol prior to infection; I-B – turkeys immunomodulated with β-glucans and MOS prior to infection; C – control turkeys not receiving immunomodulators; HEV+ – turkeys infected with haemorrhagic enteritis adenovirus at 42 days of life; HEV− – uninfected turkeys. Values in the same column with different superscripts (a–d) differ significantly at P < 0.05 in Duncan’s multiple-range test
Mean percentage of IFN-γ+ cells (±SD) in splenic CD8α+ T lymphocytes collected from the examined turkeys receiving immunomodulators before the day of infection with HEV
Group | Mean percentage of CD8α+IFN-γ+ T cells (±SD) |
||
---|---|---|---|
3 dpi | 5 dpi | 7 dpi | |
I-M/HEV+ | 2.78cd (±0.88) | 12.00b (±0.94) | 15.99a (±0.86) |
I-M/HEV− | 5.33bd (±0.91) | 6.01d (±0.50) | 4.37c (±0.95) |
I-B/HEV+ | 2.73c (±0.61) | 9.34cd (±1.24) | 10.42a (±0.89) |
I-B/HEV− | 10.54a (±3.55) | 9.94bc (±1.09) | 7.69b (±1.11) |
C/HEV+ | 2.66c (±0.33) | 15.17a (±0.88) | 5.78c (±0.87) |
C/HEV− | 6.43b (±1.33) | 14.47a (±2.11) | 11.20a (±0.93) |
IFN-γ+ – interferon gamma–positive; SD – standard deviation; dpi – days post infection; I-M – turkeys immunomodulated with methisoprinol prior to infection; I-B – turkeys immunomodulated with β-glucans and MOS prior to infection; C – control turkeys not receiving immunomodulators; HEV+ – turkeys infected with haemorrhagic enteritis adenovirus at 42 days of life; HEV− – uninfected turkeys. Values in the same column with different superscripts (a–d) differ significantly at P < 0.05 in Duncan’s multiple-range test
At 45 dol,
The CD8α+IFN-γ+ T lymphocyte subpopulation percentage at 45 dol was the highest in Group I-B/HEV− and was 10.54 ± 3.55%. The percentages of these cells making up these subpopulations in the other groups of turkeys were statistically significantly lower. In contrast, compared to birds from other groups, the highest percentages of IFN-γ–synthesising cells within the CD8α+ T lymphocyte subpopulation were detected at 5 dpi in both control groups of turkeys, where in C/HEV+ it was 15.17 ± 0.88% and in C/HEV− it was 14.47 ± 2.11%. These percentages exceeded those of other groups by a statistically significant margin. At the last sampling (7 dpi), statistically significantly higher percentages of these cells were found in HEV-infected turkeys from Groups I-M (15.99 ± 0.86%) and I-B (10.42 ± 0.89%) and in non-infected turkeys from the control groups (11.20 ± 0.93%) compared to birds from the other groups. At the second (47 dol) and third (49 dol) samplings, the CD8α+ T lymphocyte subpopulation which was IFN-γ+ accounted for a significantly lower proportion in turkeys uninfected with HEV which received immunomodulators (Groups I-M/HEV− and I-B/HEV−) than in control turkeys of the C/HEV− group. These values were statistically significantly lower in turkeys treated with methisoprinol than in control turkeys and birds treated with Alphamune G.
Mean percentage of IFN-γ+ cells (±SD) in splenic CD4+ T lymphocytes collected from the examined turkeys receiving immunomodulators after the day of infection with HEV
Group | Mean percentage of CD4+IFN-γ+ T cells (±SD) |
||
---|---|---|---|
3 dpi | 5 dpi | 7 dpi | |
II-M/HEV+ | 2.33b (±0.48) | 10.67a (±1.12) | 5.73b (±0.93) |
II-M/HEV− | 6.13a (±0.43) | 8.06ab (±2.46) | 7.94ab (±0.91) |
II-B/HEV+ | 1.83b (±0.23) | 8.81ab (±0.44) | 3.52c (±0.45) |
II-B/HEV− | 4.69a (±0.49) | 10.41a (±2.08) | 7.86ab (±3.29) |
C/HEV+ | 2.26b (±0.41) | 7.20b (±1.32) | 3.54c (±0.45) |
C/HEV− | 5.47a (±1.45) | 7.03b (±0.98) | 4.52c (±0.17) |
IFN-γ+ – interferon gamma–positive; SD – standard deviation; dpi – days post infection; II-M – turkeys immunomodulated with methisoprinol after infection; II-B – turkeys immunomodulated with β-glucans and MOS after infection; C – control turkeys not receiving immunomodulators; HEV+ – turkeys infected with haemorrhagic enteritis adenovirus at 42 days of life; HEV− – uninfected turkeys. Values in the same column with different superscripts (a–d) differ significantly at P < 0.05 in Duncan’s multiple-range test
Mean percentage of IFN-γ+ cells (±SD) within splenic CD8α+ T lymphocytes collected from the examined turkeys receiving immunomodulators after the day of infection with HEV
Group | Mean percentage of CD8+IFN-γ+ T cells (±SD) |
||
---|---|---|---|
3 dpi | 5 dpi | 7 dpi | |
II-M/HEV+ | 2.74b (±0.35) | 17.12a (±0.96) | 10.60a (±1.16) |
II-M/HEV− | 7.16a (±0.49) | 13.02bc (±2.49) | 7.61bc (±0.87) |
II-B/HEV+ | 3.57b (±0.24) | 15.38ac (±0.90) | 8.32b (±1.44) |
II-B/HEV− | 5.73a (±0.82) | 7.21b (±2.40) | 5.70c (±1.32) |
C/HEV+ | 2.66b (±0.33) | 15.17ac (±0.88) | 5.78c (±0.87) |
C/HEV− | 6.43a (±1.33) | 14.47ac (±2.11) | 11.20a (±0.93) |
IFN-γ+ – interferon gamma–positive; SD – standard deviation; dpi – days post infection; II-M – turkeys immunomodulated with methisoprinol after infection; II-B – turkeys immunomodulated with β-glucans and MOS after infection; C – control turkeys not receiving immunomodulators; HEV+ – turkeys infected with haemorrhagic enteritis adenovirus at 42 days of life; HEV− – uninfected turkeys. Values in the same column with different superscripts (a–d) differ significantly at P < 0.05 in Duncan’s multiple-range test
On day 45, there was no statistical difference between the proportions of CD4+IFN-γ+ T cell subpopulations in the infected and immunomodulated (II-M/HEV+ and II-B/HEV+) and infected and non-immunomodulated (C/HEV+) groups or between uninfected and immunomodulated (II-M/HEV− and II-B/HEV−) and uninfected and non-immunomodulated (C/HEV−) groups. However, the percentage of subpopulations of these cells in turkeys from the infected groups (II-M/HEV+, II-B/HEV+ and C/HEV+) was statistically significantly lower than in the non-infected groups (II-M/HEV−, II-B/HEV− and C/HEV−). Two days later, the percentage of cells synthesising IFN-γ in the CD4+ T cell subpopulation was statistically significantly higher in the II-M/HEV+ (10.67 ± 1.12%) and II-B/HEV− (10.41 ± 2.08%) groups relative to the C/HEV+ (7.20 ± 1.32%) and C/HEV− (7.03 ± 0.98%) control groups. At the last collection (49 dol), the CD4+IFN-γ+ cell subpopulation sizes in the non-immunomodulated control groups and in the II-B/HEV+ group of turkeys which received Alphamune G after HEV infection were significantly smaller than those in the II-M/HEV+ and II-M/HEV− groups of turkeys receiving methisoprinol and those in the II-B/HEV− group.
On day 45, there were no statistically significant differences between the proportions of CD8α+IFN-γ+ T cell subpopulations in the three HEV-infected groups. The same was noted for the three uninfected groups. However, the percentage of subpopulations of these cells in turkeys from the infected groups was statistically significantly lower than in uninfected turkeys. At 47 dol, the percentage of cells synthesising IFN-γ in the CD8α+ T lymphocyte subpopulation was significantly higher in HEV-infected turkeys than in uninfected turkeys. The
highest value of this percentage (17.12 ± 0.96%) was recorded on this day in the II-M/HEV+ group of turkeys receiving methisoprinol after HEV infection, but it was not statistically significantly higher than that in the C/HEV+ (15.17 ± 0.88%) or C/HEV− (14.47 ± 2.11%) control groups. At the last collection (49 dol), the CD8α+IFN-γ+ T cell subpopulation sizes in Group II-M/HEV+ (10.60 ± 1.16%) and in uninfected C/HEV− control group turkeys (11.20 ± 0.93%) were significantly larger than in the other groups.
Mean percentage of IFN-γ+ cells (±SD) in splenic CD4+ T lymphocytes collected from the examined turkeys receiving immunomodulators prior to, at the time of, and after infection with HEV
Group | Mean percentage of CD4+IFN-γ+ T cells (±SD) |
||
---|---|---|---|
3 dpi | 5 dpi | 7 dpi | |
III-M/HEV+ | 3.56cd (±0.72) | 8.19cd (±0.95) | 10.17a (±0.80) |
III-M/HEV− | 8.36a (±0.74) | 7.67cd (±0.99) | 6.69bc (±0.19) |
III-B/HEV+ | 2.43c (±0.36) | 9.91abd (±0.76) | 8.37abc (±0.87) |
III-B/HEV− | 4.71bd (±0.88) | 10.98a (±0.51) | 8.02ac (±1.73) |
C/HEV+ | 2.26c (±0.41) | 7.20c (±1.32) | 3.54d (±0.45) |
C/HEV− | 5.47b (±1.45) | 7.03c (±0.98) | 4.52d (±0.17) |
IFN-γ+ – interferon gamma–positive; SD – standard deviation; dpi – days post infection; III-M – turkeys immunomodulated with methisoprinol prior to, at the time of, and after infection; III-B – turkeys immunomodulated with β-glucans and MOS prior to, at the time of, and after infection; C – control turkeys not receiving immunomodulators; HEV+ – turkeys infected with haemorrhagic enteritis adenovirus at 42 days of life; HEV− – uninfected turkeys. Values in the same column with different superscripts (a–d) differ significantly at P < 0.05 in Duncan’s multiple-range test
Mean percentage of IFN-γ+ cells (±SD) within splenic CD8α+ T lymphocytes collected from the examined turkeys receiving immunomodulators prior to, at the time of, and after infection with HEV
Group | Mean percentage of IFN-γ+ CD8+ T cells (±SD) |
||
---|---|---|---|
3 dpi | 5 dpi | 7 dpi | |
III-M/HEV+ | 5.60bd (±1.94) | 12.55bc (±1.08) | 11.42a (±0.89) |
III-M/HEV− | 9.99a (±1.93) | 11.84c (±1.07) | 6.95b (±1.30) |
III-B/HEV+ | 3.22cd (±0.87) | 16.42a (±0.88) | 11.46a (±0.84) |
III-B/HEV− | 4.35bcd (±0.84) | 7.51d (±1.91) | 6.87b (±0.84) |
C/HEV+ | 2.66c (±0.33) | 15.17ab (±0.88) | 5.78b (±0.87) |
C/HEV− | 6.43b (±1.33) | 14.47ab (±2.11) | 11.20a (±0.93) |
IFN-γ+ – interferon gamma–positive; SD – standard deviation; dpi – days post infection; III-M – turkeys immunomodulated with methisoprinol prior to, at the time of, and after infection; III-B – turkeys immunomodulated with β-glucans and MOS prior to, at the time of, and after infection; C – control turkeys not receiving immunomodulators; HEV+ – turkeys infected with haemorrhagic enteritis adenovirus at 42 days of life; HEV− – uninfected turkeys. Values in the same column with different superscripts (a–d) differ significantly at P < 0.05 in Duncan’s multiple-range test
At the first collection (45 dol), the percentage of cells synthesising IFN-γ in the CD4+ T cell subpopulation was lower in all infected turkey groups than in the uninfected HEV groups. There were no statistically significant differences between immunomodulated HEV-infected turkeys and control turkeys. The highest percentage (disregarding uninfected turkeys) (3.56 ± 0.72%) was found in birds in Group III-M/HEV+) receiving methisoprinol before and after HEV infection. At 47 days of life, a statistically significantly higher proportion of these cells was found in Groups III-B/HEV− (10.98 ± 0.51%) and III-B/HEV+ (9.91 ± 0.76%), which received Alphamune G, than in the C/HEV− (7.03 ± 0.98%) and C/HEV+ (7.20 ± 1.32%) control groups. At the last sampling, the CD4+IFN-γ+ T cell subpopulation percentage was statistically significantly higher in all groups of turkeys receiving the studied immunomodulators before and after HEV infection than in control birds. The highest proportion (10.17 ± 0.80%) of T cells being CD4+IFN-γ+ at 49 dol was reported in the group of turkeys receiving methisoprinol pre- and post HEV infection (III-M/HEV+). Additionally, the III-B/HEV+ group of turkeys which received Alphamune G before and after HEV infection had a statistically significantly higher proportion of these cells than control birds.
At 45 dol, the percentage of cells synthesising IFN-γ within the CD8α+ T cell subpopulation was statistically significantly higher in Group III-M/HEV− turkeys (9.99 ± 1.93%) than in birds from other groups. In the infected group of turkeys that received methisoprinol before and after infection, the percentage of these cells (5.60 ± 1.94%) was significantly higher compared to birds in the control group (2.66 ± 0.33%). After two days (at 47 dol), there were no statistically significant differences between any HEV-infected turkeys treated with the test immunomodulators and control birds. At the last sampling, statistically significantly higher proportions of CD8α+IFN-γ+ T cells, 11.42 ± 0.89% for Group III-M/HEV+ and 11.46 ± 0.88% for Group III-B/HEV+, were observed in HEV− infected turkeys treated with the studied immunomodulators compared to the proportion in C/HEV+ control birds, 5.78 ± 0.87%.
Results of PCR amplification of the HE virus hexon gene fragment in spleen samples taken from four turkeys from each group
Group | % of samples positive for HEV genetic material by dol/dpi |
||
---|---|---|---|
45/3 | 47/5 | 49/7 | |
I-M/HEV+ | 0 | 50 | 25 |
I-M/HEV− | 0 | 0 | 0 |
I-B/HEV+ | 25 | 75 | 25 |
I-B/HEV− | 0 | 0 | 0 |
II-M/HEV+ | 25 | 75 | 50 |
II-M/HEV− | 0 | 0 | 0 |
II-B/HEV+ | 50 | 100 | 75 |
II-B/HEV− | 0 | 0 | 0 |
III-M/HEV+ | 0 | 75 | 25 |
III-M/HEV− | 0 | 0 | 0 |
III-B/HEV+ | 0 | 75 | 50 |
III-B/HEV− | 0 | 0 | 0 |
C/HEV+ | 50 | 100 | 100 |
C/HEV− | 0 | 0 | 0 |
dol – day of life; dpi – days post infection; I-M – turkeys immunomodulated with methisoprinol prior to infection; I-B – turkeys immunomodulated with β-glucans and mannan oligosaccharides (MOS) prior to infection; II-M – turkeys immunomodulated with methisoprinol after infection; II-B – turkeys immunomodulated with β-glucans and MOS after infection; III-M – turkeys immunomodulated with methisoprinol prior to, at the time of, and after infection; III-B – III-B – turkeys immunomodulated with β-glucans and MOS prior to, at the time of, and after infection; C – control turkeys not receiving immunomodulators; HEV+ – turkeys infected with haemorrhagic enteritis adenovirus at 42 days of life; HEV− – uninfected turkeys; 25%, 50%, 75% and 100% mean that HEV genetic material was respectively detected in the 1st, in the 1st and 2nd, in the 1st, 2nd, and 3rd, and in all 4 spleens collected from four turkeys in a group on a given day
During the experiment, no fatalities occurred in infected or uninfected HEV turkeys. The level of biosecurity and the physical means of segregation in the pavilion where the experiment was conducted effectively prevented the transmission of HEV from infected to uninfected groups, as evidenced by the results of the PCR examination of the spleen samples presented in Table 8. The Polish HEV isolate used in the experiment is among the strains with low pathogenicity, which explains why there were no cases in turkeys infected with it (47). Despite the absence of cases with typical symptoms of this disease in this experiment, even non-virulent HEV strains can cause transient immunosuppression, usually resulting in secondary infections within 2–4 weeks of infection (27, 35).
The possibility of induction of immunosuppression in turkeys by both field and HEV vaccine strains imposes the need to search for any and all measures to reduce or prevent this phenomenon. Attempts to develop safe next-generation HEV vaccines are ongoing (4). Unfortunately, these vaccines were never commercially available at any time in the past and neither are they currently. Manufacturers of the classical live-HEV vaccines available in Europe expressly recommend prophylactic administration of broad-spectrum antibiotics to turkeys inoculated with their preparations. This is contrary to the intention of global programmes for the protection of the efficacy of antibiotics, which address the antibiotic use leading to an increase in antibiotic resistance. Various synthetic and natural substances are known to have a beneficial effect on the immune system of turkeys. To abate the risk of antibiotic resistance, research is underway on the possibility of prophylactic use of such substances to mitigate the effects of immunosuppression resulting from infection or HEV vaccination and to impart an adjuvant effect at the same time (25, 48, 49). The effect immunomodulators can have is the net effect of the turkeys’ immune status at the time of therapy initiation, the dose, the route of administration, the number of doses in the series, and the timing of their administration relative to the instant when the infection occurred or the action of the immunosuppressive agent began. Excessively long use or administration of unnecessarily high doses of immunomodulators may result in immune system weakness or even immunosuppression. Therefore, this research was divided into three parallel experiments in which the tested turkeys received immunomodulators before (in the first experiment), after (in the second experiment) or before and after (in the third experiment) intentional HEV infection. The effect of immunomodulation on IFN-γ synthesis by CD4+ and CD8α+ T cells isolated from the spleens of HEV-infected turkeys was investigated. Interferon secretion by different cells is a major mechanism of innate resistance to virus infections. Three types of type I interferons (α, β and λ) and type II IFN-γ have been identified in chickens (21). Turkey and chicken IFN-γ have amino acid sequences which are 97% identical, and for this reason chicken IFN shows high biological reactivity in turkeys (20, 28). It was decided to use commercially available anti-chicken IFN-γ antibodies with high cross-reactivity with turkey IFN-γ in the studies of the turkey immune system conducted in our department (22). Similar experiments are very often conducted in humans and in laboratory animals to evaluate various substances, and they seek to increase the effectiveness of vaccines or to determine the body’s response to infection (15, 34, 50). Most often, analyses of the synthesis of IFN-γ in birds within different subpopulations of cells or organs are performed by molecular methods and indicate an increase in the expression of the gene encoding IFN-γ while not confirming an increase in the level of IFN production or secretion (8, 43, 52, 53). Studies on the synthesis of IFN or certain cytokines by specific subpopulations of lymphocytes are performed extremely rarely in birds due to the high cost and degree of complexity of labelling and the need for very expensive equipment (46, 48). It is therefore difficult to relate the results of the present studies to the results of similar studies in birds available in the literature. Studies by the authors have shown that both in the CD4+ and CD8α+ T lymphocyte subpopulations, IFN-γ–synthesising cells are found in response to mitogen stimulation under
One of the immunomodulators used in the present studies was the commercial preparation Alphamune G, containing as its two active components β-glucans (β-1,3/1,6) and MOS extracted from the wall of
In human medicine, for several years great attention has been paid to methisoprinol in Poland and around the world for the treatment of immunocompromised patients or sufferers of diseases caused by certain viruses. Recently, it has also been used in adjuvant therapy in people infected with the SARS-CoV-2 virus (2). Studies on methisoprinol have demonstrated that its immunomodulatory activity is characterised by enhanced lymphocyte proliferation, cytokine and IFN-γ production, and natural killer cell cytotoxicity (7, 31, 39, 42).
In the present research, both methisoprinol in all three experiments and β-glucans and MOS in first and third experiments were shown to increase IFN-γ synthesis by CD4+ T cells in such cells isolated from the spleens of HEV− infected turkeys compared to this synthesis in control birds which were infected but received no immunomodulators. These results are in line with those obtained by other authors, who showed that regardless of whether it was used
In all experimental configurations in the present investigation, samples from HEV-infected turkeys which received methisoprinol or β-glucans and MOS contained larger CD8α+IFN-γ+ subpopulations than the C/HEV+ control group did at 3 and 7 dpi. The size difference was statistically significant at 7 dpi, whereas it was not at 3 dpi. The CD8α+IFN-γ+ T cell count was higher at 5 and 7 dpi in the HEV-infected immunomodulated groups than in the uninfected groups treated with the studied immunomodulators. This indicates that the antiviral response mechanisms were triggered by the secretion of interferons by immune cells of the HEV-infected turkeys. This is in line with the results of Rautenschlein and Sharma (38), who found a statistically significantly higher level of IFN-γ in the culture medium of
Immunomodulation may be an effective tool in alleviating the effects of immunosuppression in HEV-infected turkeys. The use of natural and synthetic immunomodulators opens up new opportunities in veterinary practice, especially in poultry flocks, and gives hope for improving the health of turkeys and reducing the administration of antibiotics to flocks, thereby improving consumer safety.